Urginafect 
Solfifenacin succinate 1 mg/ml 
Oral Suspension 
 

Therapeutic indications 
Neurogenic detrusor overactivity 
Urginafect oral suspension is indicated for treatment of neurogenic detrusor overactivity (NDO) in 
paediatric patients aged 2 to 18 years. 
Overactive bladder in adults 
Urginafect oral suspension is indicated for symptomatic treatment of urge incontinence and/or 
increased urinary frequency and urgency as may occur in patients with overactive bladder (OAB) 
syndrome.